These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 20852005)

  • 21. Single therapeutic and supratherapeutic doses of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, do not prolong the QTcF interval in healthy volunteers.
    Luo WL; Crumley T; Ebel D; Atiee GJ; Royalty J; Johnson-Levonas AO; Wagner J; Lai E
    J Clin Pharmacol; 2010 Nov; 50(11):1273-9. PubMed ID: 20107202
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of moxifloxacin on QTc and implications for the design of thorough QT studies.
    Bloomfield DM; Kost JT; Ghosh K; Hreniuk D; Hickey LA; Guitierrez MJ; Gottesdiener K; Wagner JA
    Clin Pharmacol Ther; 2008 Oct; 84(4):475-80. PubMed ID: 19238652
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The use of beat-to-beat electrocardiogram analysis to distinguish QT/QTc interval changes caused by moxifloxacin from those caused by vardenafil.
    Fossa AA; Langdon G; Couderc JP; Zhou M; Darpo B; Wilson F; Wallis R; Davis JD
    Clin Pharmacol Ther; 2011 Sep; 90(3):449-54. PubMed ID: 21814193
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A statistical assessment of QT data following placebo and moxifloxacin dosing in thorough QT studies.
    Stylianou A; Roger J; Stephens K
    J Biopharm Stat; 2008; 18(3):502-16. PubMed ID: 18470759
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Man versus machine: is there an optimal method for QT measurements in thorough QT studies?
    Darpo B; Agin M; Kazierad DJ; Layton G; Muirhead G; Gray P; Jorkasky DK
    J Clin Pharmacol; 2006 Jun; 46(6):598-612. PubMed ID: 16707406
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Absence of QTc prolongation in a thorough QT study with subcutaneous liraglutide, a once-daily human GLP-1 analog for treatment of type 2 diabetes.
    Chatterjee DJ; Khutoryansky N; Zdravkovic M; Sprenger CR; Litwin JS
    J Clin Pharmacol; 2009 Nov; 49(11):1353-62. PubMed ID: 19737980
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of the cardiac safety of fampridine-SR sustained-release tablets in a thorough QT/QTc evaluation at therapeutic and supratherapeutic doses in healthy individuals.
    March B; Cardi T
    Expert Opin Investig Drugs; 2009 Dec; 18(12):1807-15. PubMed ID: 19938897
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Period correction of the QTc of moxifloxacin with multiple predose baseline ECGs is the least variable of 4 methods tested.
    Zhang X; Silkey M; Schumacher M; Wang L; Raval H; Caulfield JP
    J Clin Pharmacol; 2009 May; 49(5):534-9. PubMed ID: 19287043
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Computerized extraction of electrocardiograms from continuous 12-lead holter recordings reduces measurement variability in a thorough QT study.
    George S; Rodriguez I; Ipe D; Sager PT; Gussak I; Vajdic B
    J Clin Pharmacol; 2012 Dec; 52(12):1891-900. PubMed ID: 22187440
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Raltegravir thorough QT/QTc study: a single supratherapeutic dose of raltegravir does not prolong the QTcF interval.
    Iwamoto M; Kost JT; Mistry GC; Wenning LA; Breidinger SA; Marbury TC; Stone JA; Gottesdiener KM; Bloomfield DM; Wagner JA
    J Clin Pharmacol; 2008 Jun; 48(6):726-33. PubMed ID: 18441333
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects.
    Barriere S; Genter F; Spencer E; Kitt M; Hoelscher D; Morganroth J
    J Clin Pharmacol; 2004 Jul; 44(7):689-95. PubMed ID: 15199073
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of baseline ECG collection on the planning, analysis and interpretation of 'thorough' QT trials.
    Sethuraman V; Sun Q
    Pharm Stat; 2009; 8(2):113-24. PubMed ID: 18481273
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Statistical consideration in testing for assay sensitivity in a "thorough" QT study.
    Sethuraman V; Wu S; Wang J
    J Biopharm Stat; 2010 May; 20(3):641-53. PubMed ID: 20358442
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Literature review and pilot studies of the effect of QT correction formulas on reported beta2-agonist-induced QTc prolongation.
    Milic M; Bao X; Rizos D; Liu F; Ziegler MG
    Clin Ther; 2006 Apr; 28(4):582-90. PubMed ID: 16750469
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of the selective alpha 1a-adrenoceptor antagonist silodosin on ECGs of healthy men in a randomized, double-blind, placebo- and moxifloxacin-controlled study.
    Morganroth J; Lepor H; Hill LA; Volinn W; Hoel G
    Clin Pharmacol Ther; 2010 May; 87(5):609-13. PubMed ID: 20220748
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Semiautomated QT interval measurement in electrocardiograms from a thorough QT study: comparison of the grouped and ungrouped superimposed median beat methods.
    Hingorani P; Karnad DR; Ramasamy A; Panicker GK; Salvi V; Bhoir H; Kothari S
    J Electrocardiol; 2012; 45(3):225-30. PubMed ID: 22364647
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of semiautomated and fully automated methods for QT measurement during a thorough QT/QTc study: variability and sample size considerations.
    Tyl B; Kabbaj M; Fassi B; De Jode P; Wheeler W
    J Clin Pharmacol; 2009 Aug; 49(8):905-15. PubMed ID: 19542314
    [TBL] [Abstract][Full Text] [Related]  

  • 38. QT effects of duloxetine at supratherapeutic doses: a placebo and positive controlled study.
    Zhang L; Chappell J; Gonzales CR; Small D; Knadler MP; Callaghan JT; Francis JL; Desaiah D; Leibowitz M; Ereshefsky L; Hoelscher D; Leese PT; Derby M
    J Cardiovasc Pharmacol; 2007 Mar; 49(3):146-53. PubMed ID: 17414226
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Creation of a knowledge management system for QT analyses.
    Tornøe CW; Garnett CE; Wang Y; Florian J; Li M; Gobburu JV
    J Clin Pharmacol; 2011 Jul; 51(7):1035-42. PubMed ID: 20978278
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differences between study-specific and subject-specific heart rate corrections of the QT interval in investigations of drug induced QTc prolongation.
    Malik M; Hnatkova K; Batchvarov V
    Pacing Clin Electrophysiol; 2004 Jun; 27(6 Pt 1):791-800. PubMed ID: 15189536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.